Ownership and insider activity for Cogent Biosciences, Inc. (COGT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Price
| Price | $33.16 |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.3M | $28.3M | $55.7M | $37.4M | $242.2M | $219.7M | $139.9M | $53.2M | $98.2M | $312.0M |
| Short-term Investments | $27.2M | $12.7M | $22.9M | 0 | 0 | 0 | $119.4M | $212.5M | $188.9M | $588.8M |
| Receivables | $928000 | $830000 | $1.7M | $2.0M | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | $75000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $69.7M | $42.4M | $81.0M | $40.6M | $244.9M | $222.6M | $265.0M | $270.8M | $296.5M | $910.4M |
| Property, Plant & Equipment | $4.6M | $4.1M | $3.3M | $7.2M | $4.7M | $4.5M | $31.1M | $30.3M | $26.6M | $23.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $75.5M | $49.1M | $85.9M | $49.4M | $250.9M | $232.1M | $300.8M | $313.4M | $327.9M | $937.6M |
| Accounts Payable | $1.5M | $1.3M | $1.5M | $3.2M | $732000 | $3.5M | $5.8M | $10.7M | $12.0M | $9.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.5M |
| Total Current Liabilities | $8.7M | $11.2M | $24.9M | $13.2M | $13.1M | $17.1M | $26.8M | $38.2M | $55.7M | $64.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $237.2M |
| Total Liabilities | $23.2M | $20.8M | $25.7M | $17.7M | $16.2M | $17.9M | $45.1M | $55.6M | $71.6M | $301.2M |
| Retained Earnings | -$25.8M | -$51.3M | -$92.1M | -$123.9M | -$198.7M | -$271.0M | -$411.2M | -$603.6M | -$859.5M | -$1.19B |
| Total Equity | $52.4M | $28.3M | $60.2M | $31.8M | $234.7M | $214.2M | $255.7M | $257.8M | $256.3M | $636.4M |
| Total Debt | 0 | 0 | 0 | $6.0M | $5.2M | $3.2M | $19.6M | $18.9M | $17.5M | $253.2M |
| Net Debt | -$68.5M | -$41.0M | -$78.6M | -$31.4M | -$237.0M | -$216.5M | -$239.6M | -$246.9M | -$269.6M | -$647.6M |
| Working Capital | $61.0M | $31.2M | $56.1M | $27.3M | $231.8M | $205.6M | $238.1M | $232.6M | $240.8M | $846.4M |
Financial Health
| Debt / Equity | 0.46 |
| Current Ratio | 13.57 |
Profitability
| Return on Equity | -72.57% |
| Return on Invested Capital | -50.09% |
| Return on Assets | -45.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AGIO · DNLI · ETNB · GLPG · IBRX · LQDA · OCUL
Explore sector: Healthcare · Biotechnology
More sections of COGT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks